Bridgewater, NJ (USA), January 18, 2018 – Amneal Pharmaceuticals has launched budesonide capsules, 3 mg, an AB-rated equivalent to Entocort® EC this month.
Annual U.S. sales of budesonide and its generic equivalents were $187 million, according to November 2017 IQVIA™ market data. Budesonide capsules are now shipping to wholesalers, distributors and direct to the trade.
Budesonide is the first product launch of the new year for Amneal Pharmaceuticals. In 2017, the company received 45 ANDA approvals (39 final and 6 tentative), and launched 35 product families—nine of these by its injectables subsidiary Amneal Biosciences. For a complete list of Amneal products available in the U.S., visit the online catalog at amneal.com..
Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high-quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com.
All trademarks listed in this release are property of their respective owners.
Photo available upon request.